Your browser doesn't support javascript.
loading
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.
Bailey, Stefanie R; Vatsa, Sonika; Larson, Rebecca C; Bouffard, Amanda A; Scarfò, Irene; Kann, Michael C; Berger, Trisha R; Leick, Mark B; Wehrli, Marc; Schmidts, Andrea; Silva, Harrison; Lindell, Kevin A; Demato, Ashley; Gallagher, Kathleen M E; Frigault, Matthew J; Maus, Marcela V.
Affiliation
  • Bailey SR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Vatsa S; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Larson RC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Bouffard AA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Scarfò I; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Kann MC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Berger TR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Leick MB; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Wehrli M; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Schmidts A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Silva H; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Lindell KA; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Demato A; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
  • Gallagher KME; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Frigault MJ; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
Blood Cancer Discov ; 3(2): 136-153, 2022 03 01.
Article in En | MEDLINE | ID: mdl-35015685
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy, Adoptive / Hematologic Neoplasms Limits: Humans Language: En Journal: Blood Cancer Discov Year: 2022 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy, Adoptive / Hematologic Neoplasms Limits: Humans Language: En Journal: Blood Cancer Discov Year: 2022 Document type: Article Country of publication: Estados Unidos